Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Neuronal network dysfunction precedes storage and neurodegeneration in a lysosomal storage disorder
Rebecca C. Ahrens-Nicklas, Luis Tecedor, Arron F. Hall, Elena Lysenko, Akiva S. Cohen, Beverly L. Davidson, Eric D. Marsh
Rebecca C. Ahrens-Nicklas, Luis Tecedor, Arron F. Hall, Elena Lysenko, Akiva S. Cohen, Beverly L. Davidson, Eric D. Marsh
View: Text | PDF
Research Article Metabolism Neuroscience

Neuronal network dysfunction precedes storage and neurodegeneration in a lysosomal storage disorder

  • Text
  • PDF
Abstract

Accumulation of lysosomal storage material and late-stage neurodegeneration are hallmarks of lysosomal storage disorders (LSDs) affecting the brain. Yet, for most LSDs, including CLN3 disease, the most common form of childhood dementia, it is unclear what mechanisms drive neurologic symptoms. Do deficits arise from loss of function of the mutated protein or toxicity from storage accumulation? Here, using in vitro voltage-sensitive dye imaging and in vivo electrophysiology, we find progressive hippocampal dysfunction occurs before notable lysosomal storage and neuronal loss in 2 CLN3 disease mouse models. Pharmacologic reversal of lysosomal storage deposition in young mice does not rescue this circuit dysfunction. Additionally, we find that CLN3 disease mice lose an electrophysiologic marker of new memory encoding — hippocampal sharp-wave ripples. This discovery, which is also seen in Alzheimer’s disease, suggests the possibility of a shared electrophysiologic signature of dementia. Overall, our data describe new insights into previously unknown network-level changes occurring in LSDs affecting the central nervous system and highlight the need for new therapeutic interventions targeting early circuit defects.

Authors

Rebecca C. Ahrens-Nicklas, Luis Tecedor, Arron F. Hall, Elena Lysenko, Akiva S. Cohen, Beverly L. Davidson, Eric D. Marsh

×

Figure 6

CLN3–/– mice have increased spiking activity on EEG.

Options: View larger image (or click on image) Download as PowerPoint

CLN3–/– mice have increased spiking activity on EEG.
(A) EEG recordings...
(A) EEG recordings from the motor cortex of CLN3–/– (red) mice demonstrate increased frequent spiking activity (marked by asterisk), as compared with WT (black) animals. (B) Quantification of spikes from all adult animals (≥6 months of age) demonstrates increased spiking activity in CLN3–/– animals (median ± 95% CI shown). (C) Quantification of power in the major EEG frequency bands in WT and CLN3–/– animals reveals that CLN3–/– mice have decreased slow delta activity (0.1–4.0 Hz) (mean ± SEM shown). (D and E) Further evaluation of the power in the fast beta and slow delta frequency ranges shows no major difference in the ratio of delta to beta power at 6 months. However, by late-stage disease CLN3–/– mice have increased fast beta and decreased slow delta power on EEG. (F) Adult CLN3–/– mice have increased percentage of recording periods with both increased fast and high spiking activity (median ± 95% CI shown). Group sizes: n = 14 mice per genotype (4–5 per age group of 6 months, 11 months, and 18+ months). For spike quantification and quantification of spiking/high-frequency periods in panels B and F, groups were compared using Mann-Whitney U test. For frequency band analysis in panel C, groups were compared using 2-way ANOVA followed by Holm-Šídák multiple-comparisons test. For all panels: *P < 0.05, **P < 0.01, and ****P < 0.0001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts